Wells Fargo & Company Glycomimetics Inc Transaction History

Wells Fargo & Company

$410 Billion
Q1 2024

A detailed history of Wells Fargo & Company transactions in Glycomimetics Inc stock. As of the latest transaction made, Wells Fargo & Company holds 383 shares of GLYC stock, worth $107. This represents 0.0% of its overall portfolio holdings.

Number of Shares

383

Previous 377 1.59%

Holding current value

$107

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.55 - $3.49 $15 - $20	6 Added 1.59%	383 $1,000
Q4 2023 Feb 09, 2024	BUY	$1.13 - $2.54 $22 - $50	20 Added 5.6%	377 $0
Q3 2023 Nov 13, 2023	SELL	$1.29 - $1.73 $23 - $31	-18 Reduced 4.8%	357 $0
Q2 2023 Aug 15, 2023	BUY	$1.21 - $2.08 $98 - $168	81 Added 27.55%	375 $0
Q1 2023 May 12, 2023	BUY	$1.25 - $4.05 $6 - $20	5 Added 1.73%	294 $0

Q4 2022 Feb 13, 2023	BUY	$0.67 - $3.03 $4 - $21	7 Added 2.48%	289 $0
Q3 2022 Nov 14, 2022	BUY	$0.56 - $0.9 $0 - $0	1 Added 0.36%	282 $0
Q2 2022 Aug 12, 2022	BUY	$0.54 - $1.15 $14 - $29	26 Added 10.2%	281 $0
Q1 2022 May 16, 2022	BUY	$1.0 - $1.58 $1 - $1	1 Added 0.39%	255 $0
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.14 $1 - $2	1 Added 0.4%	254 $0
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $88 - $117	-49 Reduced 16.23%	253 $1,000
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $237,971 - $350,346	-110,172 Reduced 99.73%	302 $1,000
Q1 2021 May 13, 2021	BUY	$2.89 - $4.22 $13,467 - $19,665	4,660 Added 4.4%	110,474 $333,000
Q4 2020 Feb 09, 2021	BUY	$2.69 - $4.24 $148,132 - $233,488	55,068 Added 108.52%	105,814 $398,000
Q3 2020 Nov 05, 2020	SELL	$3.07 - $5.0 $473,599 - $771,335	-154,267 Reduced 75.25%	50,746 $155,000
Q2 2020 Aug 13, 2020	BUY	$2.06 - $3.76 $238,990 - $436,216	116,015 Added 130.36%	205,013 $771,000
Q1 2020 May 14, 2020	BUY	$1.83 - $5.41 $162,866 - $481,479	88,998 New	88,998 $203,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

36.8M

Call Options Held

969K

Put Options Held

636K

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.7M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Glycomimetics Inc Transaction History